{
    "q": [
        {
            "docid": "21354427_3",
            "document": "Human T-lymphotropic virus . HTLV-1 is an abbreviation for \"human T-cell lymphotropic virus type 1\", also called human T-cell leukemia type 1, a virus that has been implicated in several kinds of diseases, including HTLV-1-associated myelopathy, and as a virus cancer link for leukemia (see adult T-cell leukemia/lymphoma).HTLV-1 has six reported subtypes (subtypes A to F). The great majority of infections are caused by the cosmopolitan subtype A. HTLV was discovered by Robert Gallo and colleagues in 1980. Between 1 in 20 and 1 in 25 infected people are thought to develop cancer as a result of the virus. HTLV-1 infection is thought to spread only through dividing cells since reverse transcriptase generates proviral DNA from genomic viral RNA, and the provirus is integrated into the host genome by viral integrase after transmission. Therefore, the quantification of provirus reflects the number of HTLV-1-infected cells. So, an increase in numbers of HTLV-1-infected cells using cell division, by actions of accessory viral genes, especially Tax, may provide an enhancement of infectivity Tax expression induces proliferation, inhibits the apoptosis of HTLV-1-infected cells and, conversely, evokes the host immune response, including cytotoxic T cells, to kill virus-infected cells. Interesting, HTLV-1 Tax viral gene is known to dampen innate antiviral signaling pathways to avoid host detection and elimination, through SOCS1 and Aryl Hydrocarbon Receptor Interacting Protein (AIP).",
            "score": 182.21920812129974
        },
        {
            "docid": "402080_2",
            "document": "Human T-lymphotropic virus 1 . Human T-cell lymphotropic virus type 1 or human T-lymphotropic virus type 1 (HTLV-I), also called the adult T-cell lymphoma virus type 1, is a retrovirus of the human T-lymphotropic virus (HTLV) family that has been implicated in several kinds of diseases including very aggressive adult T-cell lymphoma (ATL), HTLV-I-associated myelopathy, uveitis, \"Strongyloides stercoralis\" hyper-infection and some other diseases. It is thought that about 1\u20135% of infected persons develop cancer as a result of the infection with HTLV-I over their lifetimes.",
            "score": 164.32468712329865
        },
        {
            "docid": "1173614_4",
            "document": "Adult T-cell leukemia/lymphoma . ATL is usually a highly aggressive non-Hodgkin's lymphoma with no characteristic histologic appearance except for a diffuse pattern and a mature T-cell phenotype. Circulating lymphocytes with an irregular nuclear contour (leukemic cells) are frequently seen. Several lines of evidence suggest that HTLV-1 causes ATL. This evidence includes the frequent isolation of HTLV-1 from patients with this disease and the detection of HTLV-1 proviral genome in ATL leukemic cells. ATL is frequently accompanied by visceral involvement, hypercalcemia, skin lesions, and lytic bone lesions. Bone invasion and osteolysis, features of bone metastases, commonly occur in the setting of advanced solid tumors, such as breast, prostate, and lung cancers, but are less common in hematologic malignancies. However, patients with HTLV-1\u2013induced ATL and multiple myeloma are predisposed to the development of tumor-induced osteolysis and hypercalcemia. One of the striking features of ATL and multiple myeloma induced bone disease is that the bone lesions are predominantly osteolytic with little associated osteoblastic activity. In patients with ATL, elevated serum levels of IL-1, TGF\u03b2, PTHrP, macrophage inflammatory protein (MIP-1\u03b1), and receptor activator of nuclear factor-\u03baB ligand (RANKL) have been associated with hypercalcemia. Immunodeficient mice that received implants with leukemic cells from patients with ATL or with HTLV-1\u2013infected lymphocytes developed hypercalcemia and elevated serum levels of PTHrP. Most patients die within one year of diagnosis.",
            "score": 135.14346647262573
        },
        {
            "docid": "402080_3",
            "document": "Human T-lymphotropic virus 1 . Adult T-cell lymphoma (ATL) was discovered in 1977 in Japan. The symptoms of ATL were different from other lymphomas known at the time. It was suggested that ATL is caused by the infection of a retrovirus called ATLV. Strikingly, ATLV had the transforming activity in vitro. These studies established that the retrovirus infection is the cause of ATL. The retrovirus is now generally called HTLV-I because later studies proved that ATLV is the same as the firstly identified human retrovirus called HTLV discovered by Bernard Poiesz and Francis Ruscetti and their co-workers in the laboratory of Robert C. Gallo at the National Cancer Institute. Infection with HTLV-I, like infection with other retroviruses, probably occurs for life. A patient infected with HTLV can be diagnosed when antibodies against HTLV-1 are detected in the serum.",
            "score": 141.9468915462494
        },
        {
            "docid": "8209464_3",
            "document": "Tax gene product . HTLV-1 causes an aggressive form of leukaemia: adult T cell leukaemia (ATL), and Tax has largely been implicated in the oncogenic potential of this virus. In addition to Tax's ability to promote the transcription of viral proteins in the nucleus, it also regulates many human genes. It does this by modulating the activity of several signaling pathways such as: CREB/ATF, NF-\u03baB, AP-1 and SRF. Tax modulates cellular processes by protein-protein interaction (binding with proteins), transcriptional activation (promoting the production of proteins) and transcriptional repression (inhibiting the production of proteins). Cellular processes that Tax dysregulates to produce cancerous cells include the cell cycle and the maintenance of genomic integrity. The cell cycle has four stages (G1, S, G2 and M) and Tax is known to accelerate the transition between G1 and S phase. Two DNA repair pathways (base excision repair and nucleotide excision repair) are affected by Tax, leading to mutations in DNA; a classical hallmark of cancer. Tax also causes aneuploidy (abnormal chromosome numbers), which is a possible cause of transformation (normal cells becoming cancer cells). Many proteins are involved in these processes, including cyclins and cell cycle checkpoint proteins (p53 and Rb). Interesting, HTLV-1 Tax viral gene is known to dampen innate antiviral signaling pathways to avoid host detection and elimination, through SOCS1 and Aryl Hydrocarbon Receptor Interacting Protein (AIP).",
            "score": 99.83857560157776
        },
        {
            "docid": "37783228_18",
            "document": "William A. Haseltine . In 1979 the first human retrovirus to cause a human disease was discovered, the Human T cell leukemia Virus (HTLV). HTLV is sexually transmitted from men to women, by women to their children and by blood transfusions. The disease, T-cell leukemia, arises decades after infection. Haseltine and his laboratory discovered that HTLV carried a novel gene, called the transactivator X (now called \"tax\"). Over the next few years, Haseltine and his colleagues showed that \"tax\" is the gene responsible for the cancers. 92, Haseltine spent the summer of 1983 as a visiting professor at the University of Kyoto working with Japanese scientists studying the Human T cell Leukemia virus, a virus endemic to Japan.",
            "score": 136.2208812236786
        },
        {
            "docid": "6519036_18",
            "document": "Thromboxane receptor . Activation of TP receptors stimulates vascular endothelial cell pro-inflammatory responses such as increased expression of cell surface adhesion proteins (i.e. ICAM-1, VCAM-1, and E-selectin); stimulates apoptosis (i.e. cell death) of CD4+ and CD8+ lymphocytes; causes the chemokinesis (i.e. cell movement) of native T cells; and impairs the adhesion of dendritic cells to T cells thereby inhibiting dendritic cell-dependent proliferation of T cells. TP deficient mice exhibit an enhanced contact hypersensitivity response to DNFB thymocytes in the thymus of these deficient mice are resistant to lipopolysaccharide-induced apoptosis. TP receptor-depleted mice also gradually develop with age extensive lymphadenopathy and, associated with this, increased immune responses to foreign antigens. These studies indicate that TXA2-TP signaling functions as a negative regulator of DC-T cell interactions and possibly thereby the acquisition of acquired immunity in mice. Further studies are needed to translate these mouse studies to humans.",
            "score": 119.98600232601166
        },
        {
            "docid": "402080_23",
            "document": "Human T-lymphotropic virus 1 . Treatment of opportunistic infections varies depending on the type of disease and ranges from careful observation to aggressive chemotherapy and antiretroviral agents. Adult T cell lymphoma is a common complication of HTLV infection and requires aggressive chemotherapy, typically R-CHOP. Other treatments for ATL in HTLV infected patients include interferon alpha, zidovudine with interferon alpha and CHOP with arsenic trioxide. Treatments for HTLV myelopathy are even more limited and focus mainly on symptomatic therapy. Therapies studied include corticosteroids, plasmapheresis, cyclophosphamide, and interferon, which may produce a temporary symptomatic improvement in myelopathy symptoms.",
            "score": 122.49492025375366
        },
        {
            "docid": "35036168_2",
            "document": "NKG2D . NKG2D is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors. NKG2D is encoded by \"KLRK1\" gene which is located in the NK-gene complex (NKC) situated on chromosome 6 in mice and chromosome 12 in humans. In mice, it is expressed by NK cells, NK1.1 T cells, \u03b3\u03b4 T cells, activated CD8 \u03b1\u03b2 T cells and activated macrophages. In humans, it is expressed by NK cells, \u03b3\u03b4 T cells and CD8 \u03b1\u03b2 T cells. NKG2D recognizes induced-self proteins from MIC and RAET1/ULBP families which appear on the surface of stressed, malignant transformed, and infected cells.",
            "score": 112.28448414802551
        },
        {
            "docid": "18877437_10",
            "document": "History and naming of human leukocyte antigens . Late in 1973 a pair of researchers in Australia, Rolf Zinkernagel and Peter Doherty made a revelatory discovery that altered the thinking of immunologists forever. The pair was doing research on viral infections in mice and noticed that T-cells that prevented viral infections in some mice wouldn't always prevent the same infection in other mice. After looking at the MHCs present in the mice, they realized that cytotoxic T-cells could only identify virus infections in cells with the right Class I compatibility gene. Traditional thinking was that the immune system identified infections directly but this discovery turned that theory on its head. Compatibility genes were essential in immune system mediated viral clearing. The pair coined the term \"MHC Restriction\" to describe this relationship between T-cells, specific MHC proteins, and viral detection. In 1975, in an article in the journal \"Lancet\", they introduced the idea of \"altered self\", meaning that viruses alter the MHC proteins and this alteration is detected by T-cells. For their work they won the 1996 Nobel Prize. It took the work of many others to determine how T-cells made this identification.",
            "score": 116.7071875333786
        },
        {
            "docid": "402080_13",
            "document": "Human T-lymphotropic virus 1 . The term viral tropism refers to which cell types HTLV-I infects. Although HTLV-1 is primarily found in CD4+ T cells, other cell types in the peripheral blood of infected individuals have been found to contain HTLV-1, including CD8+ T cells, dendritic cells and B cells. HTLV-I entry is mediated through interaction of the surface unit of the virion envelope glycoprotein (SU) with its cellular receptor GLUT1, a glucose transporter, on target cells.",
            "score": 131.93421387672424
        },
        {
            "docid": "21410982_7",
            "document": "Human T-lymphotropic virus 2 . In the 1980s, HTLV-2 was identified in a patient with an unidentified T cell lymphoproliferative disease that was described as having characteristics similar to the B cell disorder, hairy cell leukemia. HTLV-2 was identified in a second patient with a T cell lymphoproliferative disease; this patient later developed hairy cell leukemia, but HTLV-2 was not found in the hairy cell clones. The cause of hairy cell leukemia is not known, but it is no longer believed to be related to viral infections.",
            "score": 131.8179259300232
        },
        {
            "docid": "2378970_6",
            "document": "HIV disease progression rates . During the initial weeks after HIV infection, qualitative differences in the cell-mediated immune response are observed that correlate with different disease progression rates (i.e., rapid progression to WHO stage 4 and the rapid loss of CD4+ T cell levels versus normal to slow progression to WHO stage 4 and the maintenance of CD4+ T cell counts above 500/\u00b5l). The appearance of HIV-1-specific CD8+ cytotoxic T cells (CTLs) early after primo-infection has been correlated with the control of HIV-1 viremia. The virus which escapes this CTL response have been found to have mutations in specific CTL epitopes. Individuals with a broad expansion of the V-beta chain of the T cell receptor of CD8+ T cells during primo-infection appear to have low levels of virus six to twelve months later, which is predictive of relatively slow disease progression. In contrast, individuals with an expansion of only a single subset of the V-beta chain of the CD8+ T cells are not able to control HIV levels over time, and thus have high viral loads six to twelve months later. LTNP\u2019s have also been shown to have a vigorous proliferation of circulating activated HIV-1-specific CD4+ T cell and CTL response against multiple epitopes with no detectable broadly cross-reactive neutralizing antibodies in the setting of an extremely low viral load. However, a few reports have correlated the presence of antibodies against Tat in LTNP status.",
            "score": 97.85675537586212
        },
        {
            "docid": "14157278_11",
            "document": "PD-L1 . It appears that upregulation of PD-L1 may allow cancers to evade the host immune system. An analysis of 196 tumor specimens from patients with renal cell carcinoma found that high tumor expression of PD-L1 was associated with increased tumor aggressiveness and a 4.5-fold increased risk of death.  Many PD-L1 inhibitors are in development as immuno-oncology therapies and are showing good results in clinical trials. Clinically available examples include Durvalumab, atezolizumab and avelumab. In normal tissue, feedback between transcription factors like STAT3 and NF-\u03baB restricts the immune response to protect host tissue and limit inflammation. In cancer, loss of feedback restriction between transcription factors can lead to increased local PD-L1 expression, which could limit the effectiveness of systemic treatment with agents targeting PD-L1. In a mouse model of intracellular infection, \"L. monocytogenes\" induced PD-L1 protein expression in T cells, NK cells, and macrophages. PD-L1 blockade (using blocking antibodies) resulted in increased mortality for infected mice. Blockade reduced TNF\u03b1 and nitric oxide production by macrophages, reduced granzyme B production by NK cells, and decreased proliferation of \"L. monocytogenes\" antigen-specific CD8 T cells (but not CD4 T cells). This evidence suggests that PD-L1 acts as a positive costimulatory molecule in intracellular infection.",
            "score": 99.10580909252167
        },
        {
            "docid": "24678469_6",
            "document": "Lutzner cells . In Lutzner cells, there is a mutation in the T-cell receptor that inhibits antigens like CD8 and CD7, but stimulates the over production of other antigens like CD4. This mutation is a clonal gene rearrangement at the TCR-\u03b3 gene. Clonal gene rearrangements create novel or new surface antibodies during early differentiation. Since these mutated antibodies are created early on, they are able to undergo mitosis and produce new T-cell lymphocytes that also contain the novel antigens. The abnormal quantity of T-cell receptors occurs because they are selected for since they express new qualities. CD4+ is the receptor that is selected for and increases in number in Lutzner cells. The neoplastic T-cells produce cytokines which active the expression of eosinophils and suppress the ability of T-cells to initiate an immune response. Since T-cell activity is lessened, the cells are not able to respond to invaders. Invaders are allowed to grow and produce lesions, and as the lesions increase in size the T-cell antigen is lost. Once this antigen is lost, the T-cell antibodies will never be able to detect the pathogen, allowing the pathogen to increase in size and cause an infection to occur. This leads to the development of non-Hodgkin\u2019s lymphoma such as Mycosis Fungoides and S\u00e9zary Syndrome.",
            "score": 93.15390634536743
        },
        {
            "docid": "402080_4",
            "document": "Human T-lymphotropic virus 1 . HTLV-1 is a retrovirus belonging to the family retroviridae and the genus deltaretrovirus. It has a positive-sense RNA genome that is reverse transcribed into DNA and then integrated into the cellular DNA. Once integrated, HTLV-1 continues to exist only as a provirus which can spread from cell to cell through a viral synapse. Few, if any, free virions are produced and there is usually no detectable virus in the blood plasma though the virus is present in genital secretions. Like HIV, HTLV-1 predominately infects CD4+ T cells.",
            "score": 134.26475191116333
        },
        {
            "docid": "21354427_11",
            "document": "Human T-lymphotropic virus . While there is no present licensed vaccine, there are many factors which make a vaccine against HTLV-1 feasible. The virus displays relatively low antigenic variability, natural immunity does occur in humans, and experimental vaccination using envelope antigens has been shown to be successful in animal models. Plasmid DNA vaccines elicit potent and protective immune responses in numerous small-animal models of infectious diseases. However, their immunogenicity in primates appears less potent. In the past two decades a large initiative has been put forth to understand the biological and pathogenic properties of the human T-cell lymphotropic virus type 1 (HTLV-1); this has ultimately led to the development of various experimental vaccination and therapeutic strategies to combat HTLV-1 infection. These strategies include the development of envelope glycoprotein derived B-cell epitopes for the induction of neutralizing antibodies, as well as a strategy to generate a multivalent cytotoxic T-lymphocyte (CTL) response against the HTLV-1 Tax antigen. A vaccine candidate that can elicit or boost anti-gp46 neutralizing antibody response may have a potential for prevention and therapy against HTLV-1 infection.",
            "score": 147.01755094528198
        },
        {
            "docid": "402080_14",
            "document": "Human T-lymphotropic virus 1 . HTLV-1 is also associated with adult T-cell leukemia/lymphoma and has been quite well studied in Japan. The time between infection and onset of cancer also varies geographically. It is believed to be about sixty years in Japan and less than forty years in the Caribbean. The cancer is thought to be due to the pro-oncogenic effect of viral RNA incorporated into host lymphocyte DNA. Chronic stimulation of the lymphocytes at the cytokine level may play a role in the development of the malignancy. The lymphoma ranges from a very indolent and slowly progressive type to a very aggressive and nearly uniformly lethal proliferative type.",
            "score": 134.33247685432434
        },
        {
            "docid": "35949206_11",
            "document": "Pathophysiology of HIV/AIDS . Recent studies employed an ex vivo human lymphoid aggregate culture (HLAC) system formed with fresh human tonsil or spleen tissue to model molecular and cellular events in human tissues during in vivo HIV infection. These studies found that >95% of CD4 T cells die because of abortive HIV infection. These dying cells are resting and thus are nonpermissive for productive HIV infection. Full viral replication was limited to the \u223c5% of activated CD4 T cells present in these tissues; these cells die by apoptosis. Abortive HIV infection occurs due to slowing of reverse transcription promoting cytosolic DNA accumulation. This viral DNA is sensed by gamma-interferon-inducible protein 16 (IFI16), which produces an innate immune response against the virus by activating caspase 1 in IFI16 inflammasomes and inducing pyroptosis, a highly inflammatory form of programmed cell death. These findings cast CD4 T-cell death during HIV infection in a different light. Rather than the virus playing a major role, it is the host response to viral DNA produced during abortive infection that triggers CD4 T-cell death. Further, these findings identify novel drug targets that may be exploited to both block CD4 T cell demise and the chronic inflammatory response generated during pyroptosis.",
            "score": 121.27678656578064
        },
        {
            "docid": "1171686_14",
            "document": "Regulatory T cell . Studies of human subjects with a history of leishmania infection suggest that modulation of CD8 suppressor T cells is, at least partly, mediated by cytokines. Leishmania specific CD4 helper T cells predominate in adults with strong protective immunity (skin-test positive with no history of clinical infection). When added to autologous leishmania infected macrophages these T cells cause parasite death and secretion of large amounts of interferon-gamma and lymphotoxin. CD8 T suppressor cells predominate in patients with no protective immunity (visceral leishmaniasis patients). When added to autologous peripheral blood mononuclear cells isolated after successful treatment, these T cells inhibit interferon-gamma secretion and proliferation and increase interleukin-6 and interleukin-10 secretion. A soluble factor(s) generated by antigen or phytohemagglutinin stimulation of leishmania-specific CD4 helper T cells from skin-test positive adults killed CD8 T cells but not CD4 helper T cells when added to culture media. Soluble factors generated by antigen stimulation of peripheral blood mononuclear cells from skin-test positive adults prevented CD8 suppressor T cell mediated increases in interleukin-10 secretion. These findings suggest that antigen stimulation of CD4 helper T cells results in production of cytokines that kill or down regulate CD8 T suppressor cells. Once the leishmania infection has been eliminated and leishmania antigens are gone, CD8 T suppressor cells down-regulate CD4 T helper cells. Isolation of cytokines that inhibit and kill CD8 T suppressor cells might be useful in treating diseases that involve immune suppression such as leishmaniasis, AIDS, and certain cancers.",
            "score": 100.35008203983307
        },
        {
            "docid": "2378970_11",
            "document": "HIV disease progression rates . Coinfections or immunizations may enhance viral replication by inducing a response and activation of the immune system. This activation facilitates the three key stages of the viral life cycle: entry to the cell; reverse transcription and proviral transcription. Chemokine receptors are vital for the entry of HIV into cells. The expression of these receptors is inducible by immune activation caused through infection or immunization, thus augmenting the number of cells that are able to be infected by HIV-1. Both reverse transcription of the HIV-1 genome and the rate of transcription of proviral DNA rely upon the activation state of the cell and are less likely to be successful in quiescent cells. In activated cells there is an increase in the cytoplasmic concentrations of mediators required for reverse transcription of the HIV genome. Activated cells also release IFN-alpha which acts on an autocrine and paracrine loop that up-regulates the levels of physiologically active NF-kappa B which activates host cell genes as well as the HIV-1 LTR. The impact of co-infections by micro-organisms such as \"Mycobacterium tuberculosis\" can be important in disease progression, particularly for those who have a high prevalence of chronic and recurrent acute infections and poor access to medical care. Often, survival depends upon the initial AIDS-defining illness. Co-infection with DNA viruses such as HTLV-1, herpes simplex virus-2, varicella zoster virus and cytomegalovirus may enhance proviral DNA transcription and thus viral load as they may encode proteins that are able to trans-activate the expression of the HIV-1 pro-viral DNA. Frequent exposure to helminth infections, which are endemic in Africa, activates individual immune systems, thereby shifting the cytokine balance away from an initial Th1 cell response against viruses and bacteria which would occur in the uninfected person to a less protective T helper 0/2-type response. HIV-1 also promotes a Th1 to Th0 shift and replicates preferentially in Th2 and Th0 cells. This makes the host more susceptible to and less able to cope with infection with HIV-1, viruses and some types of bacteria. Ironically, exposure to dengue virus seems to slow HIV progression rates temporarily.",
            "score": 103.14880359172821
        },
        {
            "docid": "14170_3",
            "document": "HIV . HIV infects vital cells in the human immune system such as helper T cells (specifically CD4 T cells), macrophages, and dendritic cells. HIV infection leads to low levels of CD4 T cells through a number of mechanisms, including pyroptosis of abortively infected T cells, apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4 T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4 T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections, leading to the development of AIDS.",
            "score": 107.99835920333862
        },
        {
            "docid": "21354427_2",
            "document": "Human T-lymphotropic virus . The human T-lymphotropic virus, human T-cell lymphotropic virus, or human T-cell leukemia-lymphoma virus (HTLV) family of viruses are a group of human retroviruses that are known to cause a type of cancer called adult T-cell leukemia/lymphoma and a demyelinating disease called HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). The HTLVs belong to a larger group of primate T-lymphotropic viruses (PTLVs). Members of this family that infect humans are called HTLVs, and the ones that infect Old World monkeys are called Simian T-lymphotropic viruses (STLVs). To date, four types of HTLVs (human T-lymphotropic virus 1 [HTLV-1], human T-lymphotropic virus 2 [HTLV-2], HTLV-3, and HTLV-4) and four types of STLVs (STLV-1, STLV-2, STLV-3, and STLV-5) have been identified. HTLV types HTLV-1 and HTLV-2 viruses are the first retroviruses which were discovered. Both belong to the oncovirus subfamily of retroviruses and can transform human lymphocytes so that they are self-sustaining in vitro. The HTLVs are believed to originate from intraspecies transmission of STLVs. The HTLV-1 genome is diploid, composed of two copies of a single-stranded RNA virus whose genome is copied into a double-stranded DNA form that integrates into the host cell genome, at which point the virus is referred to as a provirus. A closely related virus is bovine leukemia virus BLV. The original name for HIV, the virus that causes AIDS, was HTLV-3. Confusingly, however, since reassignment, the virus now called HTLV-3 is not HIV.",
            "score": 150.5216338634491
        },
        {
            "docid": "1171686_23",
            "document": "Regulatory T cell . A number of different methods are employed in research to identify and monitor Treg cells. Originally, high expression of CD25 and CD4 surface markers was used (CD4CD25 cells). This is problematic as CD25 is also expressed on non-regulatory T cells in the setting of immune activation such as during an immune response to a pathogen. As defined by CD4 and CD25 expression, regulatory T cells comprise about 5\u201310% of the mature CD4 T cell subpopulation in mice and humans, while about 1\u20132% of Treg can be measured in whole blood. The additional measurement of cellular expression of Foxp3 protein allowed a more specific analysis of Treg cells (CD4CD25Foxp3 cells). However, Foxp3 is also transiently expressed in activated human effector T cells, thus complicating a correct Treg analysis using CD4, CD25 and Foxp3 as markers in humans. Therefore, some research groups use another marker, the absence or low-level expression of the surface protein CD127 in combination with the presence of CD4 and CD25. Several additional markers have been described, e.g., high levels of CTLA-4 (cytotoxic T-lymphocyte associated molecule-4) and GITR (glucocorticoid-induced TNF receptor) are also expressed on regulatory T cells, however the functional significance of this expression remains to be defined. There is a great interest in identifying cell surface markers that are uniquely and specifically expressed on all Foxp3-expressing regulatory T cells. However, to date no such molecule has been identified.",
            "score": 98.0733904838562
        },
        {
            "docid": "28677542_5",
            "document": "TOL101 . There are numerous agents currently under investigation that are capable of modulating T cells. Currently used agents include anti-thymocyte globulin(ATG) and alemtuzumab, which not only affect T cells, but are also capable of modulating many other aspects of the immune system, often resulting in long-term broad spectrum immune suppression. Antibodies specific for CD3 such as teplizumab and otelixizumab show increased specificity for T cells compared to ATG and alemtuzumab, but are still associated with infection and cytokine release syndrome. Targeting the \u03b1\u03b2 T cells with TOL101 may reduce these issues through two mechanisms. First, infections are expected to be reduced through the preservation of \u03b3\u03b4 T cells, which have been shown to play an important role in controlling viruses such as cytomegalovirus (CMV), often observed in antibody treated patients. Second, reductions in cytokine release are expected when targeting the \u03b1\u03b2 TCR because, unlike CD3 proteins, the \u03b1\u03b2 TCR contains none of the immunoreceptor tyrosine-based activation motifs (ITAMS) required for T cell activation.",
            "score": 80.62372863292694
        },
        {
            "docid": "14876545_7",
            "document": "FGL2 . In addition to its constitutive secretion by CD4+ and CD8+ T cells, the secreted form of FGL2 (sFGL2) can be inducibly secreted by Foxp3+ CD4+ CD25+ T regulatory cells (Ts). Such T cells play a vital role in dampening the immune response after the clearance of an infection to prevent sterile inflammation. These cells also play a fundamental role in maintaining self tolerance by suppressing the activation and expansion of self-reactive lymphocytes that may instigate autoimmunity. Through their roles in immune homeostasis, it has been shown that depletion of the T cell population in murine models for disease lead to enhanced immune responses to a variety of infectious agents including hepatitis C virus (HCV). Additionally, patients with a chronic HCV infection were shown to have higher counts of T cells in peripheral blood when compared with successfully treated or healthy controls.",
            "score": 92.46412110328674
        },
        {
            "docid": "19632164_11",
            "document": "Fran\u00e7oise Barr\u00e9-Sinoussi . When Francoise Barr\u00e9-Sinoussi began working on retroviruses at the Pasteur Institute there were large programs in the United States working on the association between cancer and retroviruses, so she decided to study the link between retroviruses and leukemia in mice. After the new disease emerged (not yet named AIDS), a group of French physicians came to the Pasteur Institute to ask the rather simple question: is this new disease caused by a retrovirus? After much discussion with other colleagues, including Luc Montagnier, they concluded the agent causing this new disease may be a retrovirus but it was not HTLV, the only known retrovirus at the time, because of differing defining characteristics. In the early 1980s, Barr\u00e9- Sinuossi was already familiar with the technique of detecting reverse transcriptase activity. If reverse transcriptase activity is present, it confirms that the virus is a retrovirus. In December 1982, heavy research began and clinical observations suggested that the disease attacked immune cells because of the significant CD4 cell depletion. However, the depletion of the CD4 lymphocytes made it very difficult to isolate the virus in patients with the disease later known as, AIDS. Because of the difficulty isolating an infected cell with a patient with late disease progression, Barr\u00e9-Sinuossi and her colleagues decided to use a lymph node biopsy from a patient with generalized lymphadenopathy. Generalized lymphadenopathy was a common symptom of patients in the early stages of disease progression. In the second week of checking the biopsied cell cultures for reverse transcriptase activity, enzymatic activity was detected and increased for a short time until the reverse transcriptase activity decreased dramatically after the T-lymphocytes in the culture began to die. Barr\u00e9-Sinuossi and her colleagues decided to add lymphocytes from a blood donor in order to save the culture and it proved successful after the virus transmitted to the newly added lymphocytes from the blood donor and significant reverse transcriptase activity was again detected. At this point, the virus was named LAV for Lymphadenopathy Associated Virus, which would later be renamed to HIV, the human immunodeficiency virus. 1983 marked the beginning of Barr\u00e9- Sinuossi\u2019s career researching HIV that still continues to present day. 1983 was also the year it became clear that HIV was not only a target for what was known as the 4Hs, homosexuals, hemophiliacs, Haitians and heroin addicts, but that HIV was also targeting heterosexuals- making the likelihood that the HIV related disease, AIDS, was an epidemic very high.",
            "score": 104.1655580997467
        },
        {
            "docid": "52170563_4",
            "document": "CD4+/CD8+ ratio . HIV infection leads to low levels of CD4 T cells (lowering the CD4+/CD8+ ratio) through a number of mechanisms, including pyroptosis of abortively infected CD4 T cells, apoptosis of productively infected CD4 T cells, and killing of infected CD4 T cells by CD8 cytotoxic lymphocytes that recognize productively infected cells. When CD4 T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections. Assessing the levels of viable CD4+/CD8+ T cells in HIV-infected human lymphoid tissues using flow cytometry is shown here (Figure S5). People living with HIV who have a higher CD4/CD8 ratio may have a lower HIV reservoir. A website called Game of T cells (gameoftcells.medicine.wisc.edu) offers monthly blogs about clinical conditions associated with altered CD4/CD8 ratios and a possible relationship between the HIV reservoir and the CD4/CD8 ratio.",
            "score": 102.81752967834473
        },
        {
            "docid": "32523145_8",
            "document": "CD8+ cell . CD8+ T cells have been found to play different roles in certain diseases, such as in HIV infection and in Type 1 diabetes. HIV over time has developed many strategies to evade the host cell immune system. For example, HIV has adopted very high mutation rates to allow them to escape recognition by CD8+ T cells. They are also able to down-regulate expression of surface MHC Class I proteins of cells that they infect, in order to further evade destruction by CD8+ T cells. If CD8+ T cells cannot find, recognize and bind to infected cells, the virus will not be destroyed and will continue to grow. Furthermore, it has been recently discovered that CD8+ T cells play a critical role in Type 1 diabetes. It was previously thought that this autoimmune disease was exclusively controlled by CD4+ cells - but recent studies in a diabetic mouse model showed that CD8+ T cells also engaged in the destruction of insulin-producing pancreatic cells.",
            "score": 98.80590415000916
        },
        {
            "docid": "7807280_11",
            "document": "Interleukin 21 . IL-21 may be a critical factor in the control of persistent viral infections. IL-21 (or IL-21R) knock-out mice infected with chronic LCMV (lymphocytic choriomeningitis virus) were not able to overcome chronic infection compared to normal mice. Besides, these mice with impaired IL-21 signaling had more dramatic exhaustion of LCMV-specific CD8+ T cells, suggesting that IL-21 produced by CD4+ T cells is required for sustained CD8+ T cell effector activity and then, for maintaining immunity to resolve persistent viral infection. Thus, IL-21 may contribute to the mechanism by which CD4+ T helper cells orchestrate the immune system response to viral infections.",
            "score": 103.20442533493042
        },
        {
            "docid": "12846099_2",
            "document": "Helper/suppressor ratio . The T-Lymphocyte Helper/Suppressor Profile (Helper/Suppressor ratio, T4:T8 ratio, CD4:CD8 ratio) is a basic laboratory test in which the percentage of CD3-positive lymphocytes in the blood positive for CD4 (T helper cells) and CD8 (a class of regulatory T cells) are counted and compared. Normal values (95% confidence intervals) are approximately 30-60% CD4 and 10-30% CD8 depending on age (ratio 0.9 to 3.7 in adults). One reason for abnormal results is the loss of CD4-positive cells to the Human Immunodeficiency Virus (HIV) infection.The loss of CD4-positive cells to HIV infection can result in various distortions in the ratio, as in the initial period, production of HIV specific CD8 positive cells will cause a large fall in the ratio, but subsequent immunosuppression over time may lead to overall non production of immune cells and inversion of the ratio. It has been shown that the degree of inversion of this ratio in individuals on antiretroviral therapy is indicative of the age of the infection and independently predictive of mortality associated with non HIV events.",
            "score": 92.19595170021057
        },
        {
            "docid": "1171686_4",
            "document": "Regulatory T cell . T regulatory cells are a component of the immune system that suppress immune responses of other cells. This is an important \"self-check\" built into the immune system to prevent excessive reactions. Regulatory T cells come in many forms with the most well-understood being those that express CD4, CD25, and FOXP3 (CD4+CD25+ regulatory T cells). These \"Tregs\" are different from helper T cells. Another regulatory T cell subset is Treg17 cells. Regulatory T cells are involved in shutting down immune responses after they have successfully eliminated invading organisms, and also in preventing autoimmunity. CD4+ Foxp3+ regulatory T cells have been called \"naturally occurring\" regulatory T cells to distinguish them from \"suppressor\" T cell populations that are generated in vitro. Additional regulatory T cell populations include Tr1, Th3, CD8+CD28-, and Qa-1 restricted T cells. The contribution of these populations to self-tolerance and immune homeostasis is less well defined. Foxp3 can be used as a good marker for mouse CD4+CD25+ T cells, although recent studies have also shown evidence for Foxp3 expression in CD4+CD25- T cells. In humans, Foxp3 is also expressed by recently activated conventional T-cells and thus does not specifically identify human Tregs.",
            "score": 92.14551949501038
        }
    ],
    "r": [
        {
            "docid": "21354427_3",
            "document": "Human T-lymphotropic virus . HTLV-1 is an abbreviation for \"human T-cell lymphotropic virus type 1\", also called human T-cell leukemia type 1, a virus that has been implicated in several kinds of diseases, including HTLV-1-associated myelopathy, and as a virus cancer link for leukemia (see adult T-cell leukemia/lymphoma).HTLV-1 has six reported subtypes (subtypes A to F). The great majority of infections are caused by the cosmopolitan subtype A. HTLV was discovered by Robert Gallo and colleagues in 1980. Between 1 in 20 and 1 in 25 infected people are thought to develop cancer as a result of the virus. HTLV-1 infection is thought to spread only through dividing cells since reverse transcriptase generates proviral DNA from genomic viral RNA, and the provirus is integrated into the host genome by viral integrase after transmission. Therefore, the quantification of provirus reflects the number of HTLV-1-infected cells. So, an increase in numbers of HTLV-1-infected cells using cell division, by actions of accessory viral genes, especially Tax, may provide an enhancement of infectivity Tax expression induces proliferation, inhibits the apoptosis of HTLV-1-infected cells and, conversely, evokes the host immune response, including cytotoxic T cells, to kill virus-infected cells. Interesting, HTLV-1 Tax viral gene is known to dampen innate antiviral signaling pathways to avoid host detection and elimination, through SOCS1 and Aryl Hydrocarbon Receptor Interacting Protein (AIP).",
            "score": 182.21920776367188
        },
        {
            "docid": "402080_2",
            "document": "Human T-lymphotropic virus 1 . Human T-cell lymphotropic virus type 1 or human T-lymphotropic virus type 1 (HTLV-I), also called the adult T-cell lymphoma virus type 1, is a retrovirus of the human T-lymphotropic virus (HTLV) family that has been implicated in several kinds of diseases including very aggressive adult T-cell lymphoma (ATL), HTLV-I-associated myelopathy, uveitis, \"Strongyloides stercoralis\" hyper-infection and some other diseases. It is thought that about 1\u20135% of infected persons develop cancer as a result of the infection with HTLV-I over their lifetimes.",
            "score": 164.32469177246094
        },
        {
            "docid": "21354427_2",
            "document": "Human T-lymphotropic virus . The human T-lymphotropic virus, human T-cell lymphotropic virus, or human T-cell leukemia-lymphoma virus (HTLV) family of viruses are a group of human retroviruses that are known to cause a type of cancer called adult T-cell leukemia/lymphoma and a demyelinating disease called HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). The HTLVs belong to a larger group of primate T-lymphotropic viruses (PTLVs). Members of this family that infect humans are called HTLVs, and the ones that infect Old World monkeys are called Simian T-lymphotropic viruses (STLVs). To date, four types of HTLVs (human T-lymphotropic virus 1 [HTLV-1], human T-lymphotropic virus 2 [HTLV-2], HTLV-3, and HTLV-4) and four types of STLVs (STLV-1, STLV-2, STLV-3, and STLV-5) have been identified. HTLV types HTLV-1 and HTLV-2 viruses are the first retroviruses which were discovered. Both belong to the oncovirus subfamily of retroviruses and can transform human lymphocytes so that they are self-sustaining in vitro. The HTLVs are believed to originate from intraspecies transmission of STLVs. The HTLV-1 genome is diploid, composed of two copies of a single-stranded RNA virus whose genome is copied into a double-stranded DNA form that integrates into the host cell genome, at which point the virus is referred to as a provirus. A closely related virus is bovine leukemia virus BLV. The original name for HIV, the virus that causes AIDS, was HTLV-3. Confusingly, however, since reassignment, the virus now called HTLV-3 is not HIV.",
            "score": 150.52163696289062
        },
        {
            "docid": "21354427_11",
            "document": "Human T-lymphotropic virus . While there is no present licensed vaccine, there are many factors which make a vaccine against HTLV-1 feasible. The virus displays relatively low antigenic variability, natural immunity does occur in humans, and experimental vaccination using envelope antigens has been shown to be successful in animal models. Plasmid DNA vaccines elicit potent and protective immune responses in numerous small-animal models of infectious diseases. However, their immunogenicity in primates appears less potent. In the past two decades a large initiative has been put forth to understand the biological and pathogenic properties of the human T-cell lymphotropic virus type 1 (HTLV-1); this has ultimately led to the development of various experimental vaccination and therapeutic strategies to combat HTLV-1 infection. These strategies include the development of envelope glycoprotein derived B-cell epitopes for the induction of neutralizing antibodies, as well as a strategy to generate a multivalent cytotoxic T-lymphocyte (CTL) response against the HTLV-1 Tax antigen. A vaccine candidate that can elicit or boost anti-gp46 neutralizing antibody response may have a potential for prevention and therapy against HTLV-1 infection.",
            "score": 147.01754760742188
        },
        {
            "docid": "402080_3",
            "document": "Human T-lymphotropic virus 1 . Adult T-cell lymphoma (ATL) was discovered in 1977 in Japan. The symptoms of ATL were different from other lymphomas known at the time. It was suggested that ATL is caused by the infection of a retrovirus called ATLV. Strikingly, ATLV had the transforming activity in vitro. These studies established that the retrovirus infection is the cause of ATL. The retrovirus is now generally called HTLV-I because later studies proved that ATLV is the same as the firstly identified human retrovirus called HTLV discovered by Bernard Poiesz and Francis Ruscetti and their co-workers in the laboratory of Robert C. Gallo at the National Cancer Institute. Infection with HTLV-I, like infection with other retroviruses, probably occurs for life. A patient infected with HTLV can be diagnosed when antibodies against HTLV-1 are detected in the serum.",
            "score": 141.9468994140625
        },
        {
            "docid": "37783228_18",
            "document": "William A. Haseltine . In 1979 the first human retrovirus to cause a human disease was discovered, the Human T cell leukemia Virus (HTLV). HTLV is sexually transmitted from men to women, by women to their children and by blood transfusions. The disease, T-cell leukemia, arises decades after infection. Haseltine and his laboratory discovered that HTLV carried a novel gene, called the transactivator X (now called \"tax\"). Over the next few years, Haseltine and his colleagues showed that \"tax\" is the gene responsible for the cancers. 92, Haseltine spent the summer of 1983 as a visiting professor at the University of Kyoto working with Japanese scientists studying the Human T cell Leukemia virus, a virus endemic to Japan.",
            "score": 136.22088623046875
        },
        {
            "docid": "1173614_4",
            "document": "Adult T-cell leukemia/lymphoma . ATL is usually a highly aggressive non-Hodgkin's lymphoma with no characteristic histologic appearance except for a diffuse pattern and a mature T-cell phenotype. Circulating lymphocytes with an irregular nuclear contour (leukemic cells) are frequently seen. Several lines of evidence suggest that HTLV-1 causes ATL. This evidence includes the frequent isolation of HTLV-1 from patients with this disease and the detection of HTLV-1 proviral genome in ATL leukemic cells. ATL is frequently accompanied by visceral involvement, hypercalcemia, skin lesions, and lytic bone lesions. Bone invasion and osteolysis, features of bone metastases, commonly occur in the setting of advanced solid tumors, such as breast, prostate, and lung cancers, but are less common in hematologic malignancies. However, patients with HTLV-1\u2013induced ATL and multiple myeloma are predisposed to the development of tumor-induced osteolysis and hypercalcemia. One of the striking features of ATL and multiple myeloma induced bone disease is that the bone lesions are predominantly osteolytic with little associated osteoblastic activity. In patients with ATL, elevated serum levels of IL-1, TGF\u03b2, PTHrP, macrophage inflammatory protein (MIP-1\u03b1), and receptor activator of nuclear factor-\u03baB ligand (RANKL) have been associated with hypercalcemia. Immunodeficient mice that received implants with leukemic cells from patients with ATL or with HTLV-1\u2013infected lymphocytes developed hypercalcemia and elevated serum levels of PTHrP. Most patients die within one year of diagnosis.",
            "score": 135.14346313476562
        },
        {
            "docid": "402080_14",
            "document": "Human T-lymphotropic virus 1 . HTLV-1 is also associated with adult T-cell leukemia/lymphoma and has been quite well studied in Japan. The time between infection and onset of cancer also varies geographically. It is believed to be about sixty years in Japan and less than forty years in the Caribbean. The cancer is thought to be due to the pro-oncogenic effect of viral RNA incorporated into host lymphocyte DNA. Chronic stimulation of the lymphocytes at the cytokine level may play a role in the development of the malignancy. The lymphoma ranges from a very indolent and slowly progressive type to a very aggressive and nearly uniformly lethal proliferative type.",
            "score": 134.3324737548828
        },
        {
            "docid": "402080_4",
            "document": "Human T-lymphotropic virus 1 . HTLV-1 is a retrovirus belonging to the family retroviridae and the genus deltaretrovirus. It has a positive-sense RNA genome that is reverse transcribed into DNA and then integrated into the cellular DNA. Once integrated, HTLV-1 continues to exist only as a provirus which can spread from cell to cell through a viral synapse. Few, if any, free virions are produced and there is usually no detectable virus in the blood plasma though the virus is present in genital secretions. Like HIV, HTLV-1 predominately infects CD4+ T cells.",
            "score": 134.26475524902344
        },
        {
            "docid": "52872553_12",
            "document": "Severe combined immunodeficient mice . NOD/SCID mice can be transplanted with human fetal liver, bone, thymus, and lymphoid cells from blood transplants, leading to the formation of human immune cells, such as B and T cells, within the mice. These mice are then infected with the virus and researchers are able to study how HIV attacks the human lymphocytes and causes acquired immunodeficiency syndrome (AIDS) over time. Furthermore, humanized mouse models can also be used to test potential therapies for this disease, including gene-based therapies.",
            "score": 133.8706817626953
        },
        {
            "docid": "52872553_8",
            "document": "Severe combined immunodeficient mice . SCID mice can serve many functions in research, particularly in the study of human physiology and disease. The study of human physiology in human models is often made impossible due to ethical limitations, high financial expense, and low availability of model environments. Furthermore, results gleaned from the study of human cells \"ex vivo\" may not be indicative of their functions \"in vivo\". Due to their immunodeficient state, SCID mice are able to accept human hematopoietic stem cells harvested from human bone marrow or thymus. This can lead to the development of human adaptive immune cells, such as B and T lymphocytes, within SCID mice, and for subsequent study of human cells \"in vivo\".",
            "score": 132.5253448486328
        },
        {
            "docid": "402080_13",
            "document": "Human T-lymphotropic virus 1 . The term viral tropism refers to which cell types HTLV-I infects. Although HTLV-1 is primarily found in CD4+ T cells, other cell types in the peripheral blood of infected individuals have been found to contain HTLV-1, including CD8+ T cells, dendritic cells and B cells. HTLV-I entry is mediated through interaction of the surface unit of the virion envelope glycoprotein (SU) with its cellular receptor GLUT1, a glucose transporter, on target cells.",
            "score": 131.93421936035156
        },
        {
            "docid": "21410982_7",
            "document": "Human T-lymphotropic virus 2 . In the 1980s, HTLV-2 was identified in a patient with an unidentified T cell lymphoproliferative disease that was described as having characteristics similar to the B cell disorder, hairy cell leukemia. HTLV-2 was identified in a second patient with a T cell lymphoproliferative disease; this patient later developed hairy cell leukemia, but HTLV-2 was not found in the hairy cell clones. The cause of hairy cell leukemia is not known, but it is no longer believed to be related to viral infections.",
            "score": 131.81793212890625
        },
        {
            "docid": "402080_25",
            "document": "Human T-lymphotropic virus 1 . Allogenic bone marrow transplantation has been investigated in the treatment of HTLV-1 disease with varied results. One case report describes an HTLV-1 infected woman who developed chronic refractory eczema, corneal injury and adult T cell leukemia. She was subsequently treated with allogenic stem cell transplantation and had complete resolution of symptoms. One year post-transplant, she has had no recurrence of any symptoms, and furthermore has had a decrease in her proviral load.",
            "score": 130.48068237304688
        },
        {
            "docid": "36315057_30",
            "document": "Induced stem cells . The fact that human iPSCs capable of forming teratomas not only in humans but also in some animal body, in particular in mice or pigs, allowed to develop a method for differentiation of iPSCs in vivo. For this purpose, iPSCs with an agent for inducing differentiation into target cells are injected to genetically modified pig or mouse that has suppressed immune system activation on human cells. The formed teratoma is cut out and used for the isolation of the necessary differentiated human cells by means of monoclonal antibody to tissue-specific markers on the surface of these cells. This method has been successfully used for the production of functional myeloid, erythroid and lymphoid human cells suitable for transplantation (yet only to mice). Mice engrafted with human iPSC teratoma-derived hematopoietic cells produced human B and T cells capable of functional immune responses. These results offer hope that in vivo generation of patient customized cells is feasible, providing materials that could be useful for transplantation, human antibody generation and drug screening applications. Using MitoBloCK-6 and/or PluriSIn # 1 the differentiated progenitor cells can be further purified from teratoma forming pluripotent cells. The fact, that the differentiation takes place even in the teratoma niche, offers hope that the resulting cells are sufficiently stable to stimuli able to cause their transition back to the dedifferentiated (pluripotent) state and therefore safe. A similar in vivo differentiation system, yielding engraftable hematopoietic stem cells from mouse and human iPSCs in teratoma-bearing animals in combination with a maneuver to facilitate hematopoiesis, was described by Suzuki et al. They noted that neither leukemia nor tumors were observed in recipients after intravenous injection of iPSC-derived hematopoietic stem cells into irradiated recipients. Moreover, this injection resulted in multilineage and long-term reconstitution of the hematolymphopoietic system in serial transfers. Such system provides a useful tool for practical application of iPSCs in the treatment of hematologic and immunologic diseases.",
            "score": 127.23576354980469
        },
        {
            "docid": "1094648_10",
            "document": "Hairy cell leukemia . Human T-lymphotropic virus 2 (HTLV-2) has been isolated in a small number of patients with the variant form of HCL. In the 1980s, HTLV-2 was identified in a patient with a T-cell lymphoproliferative disease; this patient later developed hairy cell leukemia (a B cell disease), but HTLV-2 was not found in the hairy cell clones. There is no evidence that HTLV-II causes any sort of hematological malignancy, including HCL.",
            "score": 124.98855590820312
        },
        {
            "docid": "1516266_8",
            "document": "Cutaneous T cell lymphoma . There is some evidence of a relationship with human T-lymphotropic virus (HTLV) with the adult T-cell leukemia/lymphoma subtype. No definitive link between any viral infection or environmental factor has been definitely shown with other CTCL subtypes.",
            "score": 122.59178924560547
        },
        {
            "docid": "402080_23",
            "document": "Human T-lymphotropic virus 1 . Treatment of opportunistic infections varies depending on the type of disease and ranges from careful observation to aggressive chemotherapy and antiretroviral agents. Adult T cell lymphoma is a common complication of HTLV infection and requires aggressive chemotherapy, typically R-CHOP. Other treatments for ATL in HTLV infected patients include interferon alpha, zidovudine with interferon alpha and CHOP with arsenic trioxide. Treatments for HTLV myelopathy are even more limited and focus mainly on symptomatic therapy. Therapies studied include corticosteroids, plasmapheresis, cyclophosphamide, and interferon, which may produce a temporary symptomatic improvement in myelopathy symptoms.",
            "score": 122.49491882324219
        },
        {
            "docid": "10104983_2",
            "document": "Bovine leukemia virus . Bovine leukemia virus (BLV) is a retrovirus which causes enzootic bovine leukosis in cattle. It is closely related to the human T\u2011lymphotropic virus type 1 (HTLV-I). BLV may integrate into the genomic DNA of B\u2011lymphocytes as a DNA intermediate (the provirus), or exist as unintegrated circular or linear forms. Besides structural and enzymatic genes required for virion production, BLV contains an oncogene coding for a protein called Tax and expresses microRNAs of unknown function. In cattle, most infected animals are asymptomatic; leukemia is rare (about 5% of infected animals), but lymphoproliferation is more frequent (30%).",
            "score": 122.10167694091797
        },
        {
            "docid": "42862295_5",
            "document": "Amanda Fisher . At Imperial, Fisher used lymphocytes as a model to analyse how gene expression patterns are transmitted through cell division. Fisher also explored the molecular basis of lineage choice. She studies the transcriptional and epigenetic mechanisms that underlie cellular differentiation and experimental reprogramming. Fisher's research activities also include pluripotency and reprogramming, polycomb repressor complexes in stem cells, cohesion function in gene expression and genome organisation with Ikaros family transcription factors (TFs). Fisher conducts her research with a cell biology and genetics approach, using current technologies to address the events involved in maintaining embryonic stem (ES) cell pluripotency versus differentiation towards mesoderm, endoderm and ectoderm, as well as the mechanisms of T cell and B cell lineage choice and differentiation. Fisher's discoveries in HIV were extensive and critical for future research of the virus's characteristics. She produced the first functional copies of HIV, allowing her and other scientists to access biologically active material for future research of the virus's genes. She determined the roles of several of the genes in HIV. These findings have been significant in studying and understanding different characteristics of HIV and Human T-lymphotropic virus (HTLV). Whilst at the NIH, Fisher developed approaches that allowed the successful introduction of exogenous DNA onto human blood cells. Two methods, protoplast fusion and electroporation, proved successful and allowed Fisher to test whether molecular clones isolated from HIV-infected cultures could generate infectious retrovirus upon transfection. Fisher showed in 1985 that molecular clones of HIV, contained within approximately 18kb of contiguous proviral DNA, were biologically active and generated cytopathic virus when introduced into primary human T-cells. This discovery was important s it established that products of the viral genome itself, rather than a cofactor or contaminant, were capable of killing human T cells and were therefore potentially capable of mediating the immunosuppressive effect of HIV. it also provided the basis for dissecting the molecular function of each of the viral genes and for developing DNA-based diagnostic tests for HIV infection. In the following 4 years, Fisher showed that the transactivator gene \"tat\" was essential for virus replication, that truncation of the 3' open reading frame disrupts virus cytopathogenicity, and that \"sor\" (now called \"vif)\" is required for efficient cell to cell transmission of HIV virus. With clinical collaborators from the Walter Reed National Military Medical Center (Redfield and Looney), Fisher showed that patient antisera displayed type-specific neutralising properties and that multiple HIV isolates derived from a single patient were biologically diverse and contained replication-competent as well as replication-incompetent cytopathic variants. These studies performed more than 20 years ago, gave some of the first hints that a successful HIV vaccine might prove difficult to engineer.",
            "score": 121.9511947631836
        },
        {
            "docid": "35949206_11",
            "document": "Pathophysiology of HIV/AIDS . Recent studies employed an ex vivo human lymphoid aggregate culture (HLAC) system formed with fresh human tonsil or spleen tissue to model molecular and cellular events in human tissues during in vivo HIV infection. These studies found that >95% of CD4 T cells die because of abortive HIV infection. These dying cells are resting and thus are nonpermissive for productive HIV infection. Full viral replication was limited to the \u223c5% of activated CD4 T cells present in these tissues; these cells die by apoptosis. Abortive HIV infection occurs due to slowing of reverse transcription promoting cytosolic DNA accumulation. This viral DNA is sensed by gamma-interferon-inducible protein 16 (IFI16), which produces an innate immune response against the virus by activating caspase 1 in IFI16 inflammasomes and inducing pyroptosis, a highly inflammatory form of programmed cell death. These findings cast CD4 T-cell death during HIV infection in a different light. Rather than the virus playing a major role, it is the host response to viral DNA produced during abortive infection that triggers CD4 T-cell death. Further, these findings identify novel drug targets that may be exploited to both block CD4 T cell demise and the chronic inflammatory response generated during pyroptosis.",
            "score": 121.27679443359375
        },
        {
            "docid": "6519036_18",
            "document": "Thromboxane receptor . Activation of TP receptors stimulates vascular endothelial cell pro-inflammatory responses such as increased expression of cell surface adhesion proteins (i.e. ICAM-1, VCAM-1, and E-selectin); stimulates apoptosis (i.e. cell death) of CD4+ and CD8+ lymphocytes; causes the chemokinesis (i.e. cell movement) of native T cells; and impairs the adhesion of dendritic cells to T cells thereby inhibiting dendritic cell-dependent proliferation of T cells. TP deficient mice exhibit an enhanced contact hypersensitivity response to DNFB thymocytes in the thymus of these deficient mice are resistant to lipopolysaccharide-induced apoptosis. TP receptor-depleted mice also gradually develop with age extensive lymphadenopathy and, associated with this, increased immune responses to foreign antigens. These studies indicate that TXA2-TP signaling functions as a negative regulator of DC-T cell interactions and possibly thereby the acquisition of acquired immunity in mice. Further studies are needed to translate these mouse studies to humans.",
            "score": 119.98600769042969
        },
        {
            "docid": "15917712_7",
            "document": "Robert Gallo . The discovery of IL-2 allowed T cells, previously thought to be dead end cells, to be grown significantly in culture for the first time, opening research into many aspects of T cell immunology. Gallo\u2019s lab later purified and biochemically characterized IL-2. This breakthrough also allowed researchers to grow T-cells and study the viruses that affect them, such as human T-cell leukemia virus, or HTLV, the first retrovirus identified in humans, which Bernard Poiesz, another post-doctoral fellow in Gallo's lab played a key role in its isolation. HTLV's role in leukemia was clarified when Kiyoshi Takatsuki and other Japanese researchers, puzzling over an outbreak of a rare form of leukemia, later independently found the same retrovirus, and both groups showed HTLV to be the cause. At the same time, a similar HTLV-associated leukemia was identified by the Gallo group in the Caribbean. In 1982, Gallo received the prestigious Lasker Award: \"For his pioneering studies that led to the discovery of the first human RNA tumor virus [the old name for retroviruses] and its association with certain leukemias and lymphomas.\" Dr. Gallo is among a unique few to win the Lasker twice. In 1986, he was awarded the Lasker, \"For determining that the retrovirus now known as HIV-1 is the cause of Acquired Immune Deficiency Syndrome (AIDS). \"Gallo has won numerous subsequent awards and prizes. Gallo was the most cited scientist in the world from 1980\u20131990, according to the Institute for Scientific Information, and he was ranked third in the world for scientific impact for the period 1983\u20132002. He has published close to 1,300 papers.",
            "score": 117.55878448486328
        },
        {
            "docid": "1173614_3",
            "document": "Adult T-cell leukemia/lymphoma . Human T cell leukemia/lymphotropic virus type 1 (HTLV-1) is believed to be the cause of it, in addition to several other diseases.",
            "score": 117.20292663574219
        },
        {
            "docid": "402080_21",
            "document": "Human T-lymphotropic virus 1 . HTLV-1, unlike the distantly related retrovirus HIV, has an immunostimulating effect which actually becomes immunosuppressive. The virus activates a subset of T-helper cells called Th1 cells. The result is a proliferation of Th1 cells and overproduction of Th1 related cytokines (mainly IFN-\u03b3 and TNF-\u03b1). Feedback mechanisms of these cytokines cause a suppression of the Th2 lymphocytes and a reduction of Th2 cytokine production (mainly IL-4, IL-5, IL-10 and IL-13). The end result is a reduction in the ability of the infected host to mount an adequate immune response to invading organisms that require a predominantly Th2 dependent response (these include parasitic infections and production of mucosal and humoral antibodies).",
            "score": 117.19378662109375
        },
        {
            "docid": "14156407_8",
            "document": "GATA2 . The \"Gata2\" gene in mice has a structure similar to its human counterpart, Deletion of both parental \"Gata2\" genes in mice is lethal by day 10 of embryogenesis due to a total failure in the formation of mature blood cells. Inactivation of one mouse \"Gata2\" gene is neither lethal nor associated with most of the signs of human GATA2 deficiency; however, these animals do show a ~50% reduction in their hematopoietic stem cells along with a reduced ability to repopulate the bone marrow of mouse recipients. The latter findings, human clinical studies, and experiments on human tissues support the conclusion that in humans both parental \"GATA2\" genes are required for sufficient numbers of hematopoietic stem cells to emerge from the hemogenic endothelium during embryogenesis and for these cells and subsequent progenitor cells to survive, self-renew, and differentiate into mature cells. As GATA2 deficient individuals age, their deficiency in hematopoietic stem cells worsens, probably as a result of factors such as infections or other stresses. In consequence, the signs and symptoms of their disease appear and/or become progressively more severe. The role of GATA2 deficiency in leading to any of the leukemia types is not understood. Likewise, the role of GATA2 overexpression in non-familial AML as well as development of the blast crisis in chronic myelogenous leukemia and progression of prostate cancer is not understood.",
            "score": 117.11255645751953
        },
        {
            "docid": "18877437_10",
            "document": "History and naming of human leukocyte antigens . Late in 1973 a pair of researchers in Australia, Rolf Zinkernagel and Peter Doherty made a revelatory discovery that altered the thinking of immunologists forever. The pair was doing research on viral infections in mice and noticed that T-cells that prevented viral infections in some mice wouldn't always prevent the same infection in other mice. After looking at the MHCs present in the mice, they realized that cytotoxic T-cells could only identify virus infections in cells with the right Class I compatibility gene. Traditional thinking was that the immune system identified infections directly but this discovery turned that theory on its head. Compatibility genes were essential in immune system mediated viral clearing. The pair coined the term \"MHC Restriction\" to describe this relationship between T-cells, specific MHC proteins, and viral detection. In 1975, in an article in the journal \"Lancet\", they introduced the idea of \"altered self\", meaning that viruses alter the MHC proteins and this alteration is detected by T-cells. For their work they won the 1996 Nobel Prize. It took the work of many others to determine how T-cells made this identification.",
            "score": 116.70719146728516
        },
        {
            "docid": "35738500_7",
            "document": "MHC multimer . MHC tetramers are used in studies of pathogen immunity and vaccine development, in evaluation of antitumor responses, in allergy monitoring and desensitization studies, and in autoimmunity. They provide an ideal means to characterize the T cells that respond to a vaccine, and they have been used to test T cell responses in many vaccine systems, including influenza, yellow fever, tuberculosis, HIV/SIV and a large number of cancer vaccine trials, including melanoma and chronic myeloid leukemia. Class II tetramers have been used for analysis of a variety of human CD4 T cell responses to pathogens, including influenza A, Borrelia, Epstein-Barr virus, CMV, Mycobacterium tuberculosis, human T-lymphotropic virus 1, hepatitis C, anthrax, severe acute respiratory syndrome virus, human papillomavirus, and HIV. Tetramer variants have been developed that, either radiolabelled or coupled to a toxin such as saporin, can be injected into live mice to modulate or even deplete specific T cell populations. Peptide\u2013MHC tetramers have also been used therapeutically. For instance, cytomegalovirus-specific T cells have been enriched to high levels of purity using magnetic bead-based enrichment for use as a therapy for stem cell transplant patients.",
            "score": 115.6024398803711
        },
        {
            "docid": "24973681_6",
            "document": "Ludwik Gross . Gross was a major proponent of the possibility that some cancers can be caused by viruses and began a long search for viral causes of murine leukemia. In the course of these studies, he isolated the Gross murine leukemia virus strain as well as the first polyomavirus, so named for its proclivity to cause cancers in multiple tissue types. Gross murine leukemia virus is a retrovirus whose counterpart in humans is human T cell lymphotropic virus I (HTLV-I), while murine polyomavirus is closely related to the human Merkel cell polyomavirus that causes most forms of Merkel cell carcinoma. Thus, Gross identified two critical animal viruses that serve as models for viruses causing cancer in humans. His encyclopedic textbook \"Oncogenic Viruses\" is still considered a leading source book for early work in the discovery of viruses causing cancer.",
            "score": 114.4109878540039
        },
        {
            "docid": "30778342_18",
            "document": "Infectious causes of cancer . Human T cell lymphotropic virus (HTLV-1) was the first human retrovirus discovered by Robert Gallo and colleagues at NIH. The virus causes Adult T-cell leukemia, a disease first described by Takatsuki and colleagues in Japan and other neurological diseases.",
            "score": 114.3716812133789
        },
        {
            "docid": "7215078_3",
            "document": "CD90 . The antigen Thy-1 was the first T cell marker to be identified. Thy-1 was discovered by Reif and Allen in 1964 during a search for heterologous antisera against mouse leukemia cells, and was demonstrated by them to be present on murine thymocytes, on T lymphocytes, and on neuronal cells. It was originally named theta (\u03b8) antigen, then Thy-1 (THYmocyte differentiation antigen 1) due to its prior identification in thymocytes (precursors of T cells in the thymus). The human homolog was isolated in 1980 as a 25kDa protein (p25) of T-lymphoblastoid cell line MOLT-3 binding with anti-monkey-thymocyte antisera. The discovery of Thy-1 in mice and humans led to the subsequent discovery of many other T cell markers, which is very significant to the field of immunology since T cells (along with B cells) are the major cellular components of the adaptive immune response.",
            "score": 114.13700866699219
        },
        {
            "docid": "14754768_2",
            "document": "IKZF1 . DNA-binding protein Ikaros also known as Ikaros family zinc finger protein 1 is a protein that in humans is encoded by the \"IKZF1\" gene. Ikaros displays crucial functions in the hematopoietic system and its loss of function has been linked to the development of lymphoid leukemia. In particular, Ikaros has been found in recent years to be a major tumor suppressor involved in human B-cell acute lymphoblastic leukemia. IKZF1 is upregulated in granulocytes, B cells, CD4 and CD8 T cells, and NK cells, and downregulated in erythroblasts, megakaryocytes and monocytes. In Ikaros knockout mice, T cells but not B cells are generated late in mouse development due to late compensatory expression of the related gene Aiolos (IKZF3). Ikaros point mutant mice are embryonic lethal due to anemia; they have severe defects in terminal erythrocyte and granulocyte differentiation, and excessive macrophage formation. SNPs located near the 3' region of IKZF1 in humans have been linked to susceptibility to childhood acute lymphoblastic leukemia (ALL) as well as type 1 diabetes. The two effects appear to be in opposite directions, with the allele marking susceptibility to ALL protecting from T1D and vice versa.",
            "score": 113.71871948242188
        }
    ]
}